| (Values in U.S. Thousands) | Dec, 2021 | Sep, 2021 | Jun, 2021 | Mar, 2021 | Dec, 2020 |
| Sales | 26,610 | 22,610 | 18,790 | 13,680 | 8,500 |
| Sales Growth | +17.69% | +20.33% | +37.35% | +60.94% | +197.20% |
| Net Income | -54,880 | -58,000 | -58,900 | -55,630 | -70,170 |
| Net Income Growth | +5.38% | +1.53% | -5.88% | +20.72% | -16.77% |
Zogenix Inc
(ZGNX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Zogenix is a specialty biopharmaceutical company focused on developing therapies for patients with rare central nervous system conditions that have limited or no treatment options. The company is currently pursuing two therapies targeting the Dravet Syndrome and the Lennox-Gastaut Syndrome.
Fiscal Year End Date: 12/31